Puma Biotechnology Inc. Reports Decline in Q3 Profit, Surpassing Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Source: NASDAQ.COM
Earnings Performance: Puma Biotechnology Inc. reported third-quarter earnings of $8.8 million ($0.17 per share), a decrease from $20.3 million ($0.41 per share) in the same period last year, but exceeded analysts' expectations of $0.09 per share.
Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $10.5 million or $0.21 per share for the quarter.
Revenue Decline: The company's revenue fell 32.3% to $54.5 million, down from $80.5 million in the previous year.
Future Guidance: Puma Biotechnology provided revenue guidance for the next quarter of $67-$70 million and a full-year revenue forecast of $220-$223 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBYI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBYI
Wall Street analysts forecast PBYI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBYI is 3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 6.320
Low
2.00
Averages
3.50
High
5.00
Current: 6.320
Low
2.00
Averages
3.50
High
5.00
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EU and India Reach Landmark Trade Agreement
- Trade Agreement Reached: Indian Prime Minister Modi announced a free trade agreement with the EU, dubbed the 'mother of all deals,' covering 25% of global GDP and a third of global trade, which is expected to significantly enhance economic cooperation and market access between the two regions.
- Positive Market Reaction: European stocks broadly rose, with the pan-European Stoxx 600 index up 0.3%, reflecting investor optimism regarding the new trade agreement while preparing for an influx of corporate earnings reports.
- Significant Industry Impact: The EU's major exports to India include machinery, transport equipment, and chemicals, while India's key exports to the EU are also machinery, chemicals, and fuels, indicating a complementary relationship that will foster collaboration and growth across multiple sectors.
- Earnings Season Kicks Off: As the earnings season begins, investors are keenly watching financial reports from ASML, Volvo, LVMH, and Deutsche Bank, with market sentiment appearing more positive in light of the new trade agreement.
Continue Reading
Puma Biotechnology Grants 10,500 Restricted Stock Units to New Employees
- Employee Incentive Program: On January 6, 2026, Puma Biotechnology approved the grant of 10,500 restricted stock units to three new non-executive employees, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Stock Vesting Arrangement: The stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued service and alignment with company growth.
- Compliance Assurance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating Puma's commitment to transparency and compliance in attracting new employees, which bolsters investor confidence.
- Support for R&D Investments: Puma's focus on innovative cancer treatment products will benefit from this incentive, helping to attract key talent to advance R&D projects, including the new drug alisertib, thereby enhancing market competitiveness.
Continue Reading